press release

Aerial Biopharma Announces Positive Results for ADX-N05 202; A Phase 2b trial for Narcolepsy

MORRISVILLE, NC –  (October 1, 2013) – Aerial BioPharma announced today positive results from a Phase 2b clinical study of ADX-N05 in patients with Excessive Daytime Sleepiness associated with narcolepsy.  After completing a successful Phase 2a proof-of concept trial in mid-2012, Aerial began the 12-week, 93 patient, Phase 2b study in September 2012 to validate the results in a larger patient population with a longer duration of treatment. “The preliminary results are remarkable and have the opportunity to have significant impact on the standard of care for patients with narcolepsy”...

Read More

ADX-NO5 Results Presented at SLEEP 2013 Meeting

BALTIMORE, MD- June 3, 2013 – Results from Aerial BioPharma’s Phase 2a clinical trial evaluating the efficacy and safety of ADX-N05 for the treatment of excessive daytime sleepiness in adult subjects with narcolepsy will be presented at the SLEEP 2013 meeting in Baltimore, MD this week.  A total of 33 patients were randomized and completed both N05 and placebo periods in this double-blind, placebo-controlled, multicenter, crossover study.  The average sleep latency across the 4 trials on the Maintenance of Wakefulness Test (MWT), an objective measure of the severity of excessive...

Read More

Aerial Biopharma Announces Closing of Second Tranche of Series A; Expects to Complete Phase 2b Trial for Narcolepsy Drug in 2013.

MORRISVILLE, NC –  (February 20, 2013) – Aerial BioPharma announced today that the company has completed the second tranche of its $12 million dollar Series A financing.  The company has now raised $9.5M, with the third and final tranche of the Series A to be completed in the fourth quarter of 2013.  The funding will allow the company to complete the Phase 2b trial for ADX-N05, the company’s lead product for the treatment of excessive daytime sleepiness associated with narcolepsy.  After positive, Phase 2a results for ADX-N05 in mid-2012, Aerial began enrolling the Phase 2b trial in...

Read More